A study in The Journal of Clinical Endocrinology & Metabolism revealed glucagon helped increase satiety in patients with type 1 diabetes and healthy lean participants. However, obese but otherwise healthy participants did not attain such benefits. Researchers said that while therapeutic agents that affect glucagon are considered "a promising avenue for research," the study indicates that treatment with glucagon might not be effective for reducing food consumption in obese people.

Related Summaries